Literature DB >> 28229294

Perioperative complications and safety of type II thyroplasty (TPII) for adductor spasmodic dysphonia.

Kenji Mizoguchi1, Hiromitsu Hatakeyama1, Saori Yanagida2, Noriko Nishizawa2, Nobuhiko Oridate3, Satoshi Fukuda1, Akihiro Homma4.   

Abstract

Type II thyroplasty (TPII) is one of the surgical options offered in the management of adductor spasmodic dysphonia (AdSD); however, there have been no detailed reports of its safety and associated complications during the perioperative period. Our aim was to assess the complications and safety of TPII. TPII was performed for consecutive 15 patients with AdSD from April 2012 through May 2014. We examined retrospectively the perioperative complications, the degree of surgical invasion, and recovery process from surgery. All patients underwent successful surgery under only local anesthesia. Vocal fold erythema was observed in 14 patients and vocal fold edema in 10 patients; however, all of them showed complete resolution within 1 month. No patient experienced severe complications such as acute airway distress or hemorrhage. Fourteen patients were able to have oral from the 1st postoperative morning, with the remaining patient able to have oral intake from the 2nd postoperative day. In addition, no patient experienced aspiration postoperatively. In conclusion, only minor complications were observed in association with TPII in this study. No dysphagia was observed postoperatively, which is an advantage over other treatments. The results of our study suggest that TPII is a safe surgical treatment for AdSD.

Entities:  

Keywords:  Laryngeal framework surgery; Local anesthesia; Perioperative period; Postoperative complication; Spasmodic dysphonia; Type II thyroplasty

Mesh:

Year:  2017        PMID: 28229294     DOI: 10.1007/s00405-017-4463-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  18 in total

1.  Type 2 thyroplasty for spasmodic dysphonia: fixation using a titanium bridge.

Authors:  Nobuhiko Isshiki; Ichiro Yamamoto; Suminori Fukagai
Journal:  Acta Otolaryngol       Date:  2004-04       Impact factor: 1.494

2.  Recurrent laryngeal nerve section for spastic dysphonia.

Authors:  H H Dedo
Journal:  Ann Otol Rhinol Laryngol       Date:  1976 Jul-Aug       Impact factor: 1.547

3.  Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.

Authors:  Daniel Novakovic; Heather H Waters; Joanna B D'Elia; Andrew Blitzer
Journal:  Laryngoscope       Date:  2011-02-04       Impact factor: 3.325

Review 4.  A functional outcome swallowing scale for staging oropharyngeal dysphagia.

Authors:  J R Salassa
Journal:  Dig Dis       Date:  1999       Impact factor: 2.404

5.  Surgical tips for type II thyroplasty for adductor spasmodic dysphonia: modified technique after reviewing unsatisfactory cases.

Authors:  Nobuhiko Isshiki; Tetsuji Sanuki
Journal:  Acta Otolaryngol       Date:  2010-02       Impact factor: 1.494

6.  Long-term voice handicap index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia.

Authors:  Tetsuji Sanuki; Eiji Yumoto; Narihiro Kodama; Ryosei Minoda; Yoshihiko Kumai
Journal:  Auris Nasus Larynx       Date:  2013-12-25       Impact factor: 1.863

7.  Development and validation of the voice handicap index-10.

Authors:  Clark A Rosen; Annie S Lee; Jamie Osborne; Thomas Zullo; Thomas Murry
Journal:  Laryngoscope       Date:  2004-09       Impact factor: 3.325

8.  Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report.

Authors:  R H Miller; G E Woodson; J Jankovic
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-06

9.  The swallowing side effects of botulinum toxin type A injection in spasmodic dysphonia.

Authors:  S E Holzer; C L Ludlow
Journal:  Laryngoscope       Date:  1996-01       Impact factor: 3.325

10.  Recurrent laryngeal nerve avulsion for treatment of spastic dysphonia.

Authors:  J L Netterville; R E Stone; C Rainey; D L Zealear; R H Ossoff
Journal:  Ann Otol Rhinol Laryngol       Date:  1991-01       Impact factor: 1.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.